|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
Q1 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
Q3 FY2014
As of Sep 30, 2014
|
Q2 FY2014
As of Jun 30, 2014
|
Q1 FY2014
As of Mar 31, 2014
|
Q4 FY2013
As of Dec 31, 2013
|
Q3 FY2013
As of Sep 30, 2013
|
Q2 FY2013
As of Jun 30, 2013
|
Q1 FY2013
As of Mar 31, 2013
|
Q4 FY2012
As of Dec 31, 2012
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Interest bearing deposits with banks | ||||||||||||||||||||
| Securities purchased under agreements to resell | ||||||||||||||||||||
| Receivables held for investment, net (including $1.7 billion at December 31, 2015 collateralizing long-term debt and net of credit loss reserves of $311 million at December 31, 2015) | ||||||||||||||||||||
| Receivables held for sale (including $195 million and $750 million at September 30, 2017 and December 31, 2016, respectively, collateralizing long-term debt) | ||||||||||||||||||||
| Properties and equipment, net | ||||||||||||||||||||
| Real estate owned | ||||||||||||||||||||
| Deferred income taxes, net | ||||||||||||||||||||
| Bank owned life insurance | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Assets of discontinued operations | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Debt: | ||||||||||||||||||||
| Due to affiliates (including $- million and $485 million at September 30, 2017 and December 31, 2016, respectively, carried at fair value) | ||||||||||||||||||||
| Long-term debt (including $253 million and $1.3 billion at September 30, 2017 and December 31, 2016, respectively, carried at fair value and $76 million and $404 million at September 30, 2017 and December 31, 2016, respectively, collateralized by receivables) | ||||||||||||||||||||
| Total debt | ||||||||||||||||||||
| Derivative related liabilities | ||||||||||||||||||||
| Liability for postretirement benefits | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Liabilities of discontinued operations | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| Redeemable preferred stock: | ||||||||||||||||||||
| Series C ($0.01 par value, 1,000 shares authorized; 1,000 shares issued and outstanding at September 30, 2017 and December 31, 2016) | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Series C Preferred Stock | ||||||||||||||||||||
| Common equity: | ||||||||||||||||||||
| Common stock ($0.01 par value, 100 shares authorized; 68 shares issued and outstanding at September 30, 2017 and December 31, 2016) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Total common equity | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
